Recombinant Human GITR Ligand / TNFSF18 Protein, Fc Tag, 50µg

Background
Tumor necrosis factor ligand superfamily member 18 (TNFSF18) is also known as Glucocorticoid - induced TNF-related ligand (GITRL or GITR Ligand), Activation - inducible TNF - related ligand (AITRL), which belongs to the tumor necrosis factor family. TNFSF18 is expressed at high levels in the small intestine, ovary, testis, kidney and endothelial cells. TNFSF18 / GITRL is up-regulated after stimulation by bacterial lipopolysaccharides (LPS). TNFSF18 Can function as costimulator and lower the threshold for T-cell activation and T-cell proliferation. TNFSF18 / GITR Ligand is important for interactions between activated T-lymphocytes and endothelial cells. TNFSF18 also mediates activation of NF-kappa-B.

Source
Recombinant Human GITR Ligand, Fc Tag (GIL-H526a) is expressed from human 293 cells (HEK293). It contains AA Gln 50 - Ser 177 (Accession # AAH69319.1).

Molecular Characterization
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 41.5 kDa. The protein migrates as 45-48 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Bioactivity
Please refer to product data sheet.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4"
Alsalloum, Shevchenko, Fisher et al
Int J Mol Sci (2023) 24 (20)
(2) "Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists"
Fromm, de Silva, Schreiber
Front Immunol (2023) 14, 1236332
(3) "Lung tumor-infiltrating Treg have divergent transcriptional profiles and function linked to checkpoint blockade response"
Dykema, Zhang, Cheung et al
Sci Immunol (2023) 8 (87), eadg1487
Showing 1-3 of 261 papers.